1
|
Pauley K, Koptiuch C, Greenberg S, Kohlmann W, Jeter J, Colonna S, Werner T, Kinsey C, Gilcrease G, Weis J, Whisenant J, Florou V, Garrido-Laguna I. Discrepancies between tumor genomic profiling and germline genetic testing. ESMO Open 2022; 7:100526. [PMID: 35780590 PMCID: PMC9511791 DOI: 10.1016/j.esmoop.2022.100526] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 06/06/2022] [Accepted: 06/09/2022] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND Tumor genomic profiling (TGP) often incidentally identifies germline pathogenic variants (PVs) associated with cancer predisposition syndromes. Methods used by somatic testing laboratories, including germline analysis, differ from designated germline laboratories that have optimized the identification of germline PVs. This study evaluated discrepancies between somatic and germline testing results, and their impact on patients. PATIENTS AND METHODS Chart reviews were carried out at a single institution for patients who had both somatic and designated germline genetic testing. Cases with discrepant results in which germline PVs were not detected by the somatic laboratory or in which variant classification differed are summarized. RESULTS TGP was carried out on 2811 cancer patients, 600 of whom also underwent designated germline genetic testing. Germline PVs were identified for 109 individuals. Discrepancies between germline genetic testing and tumor profiling reports were identified in 20 cases, including 14 PVs identified by designated germline genetic testing laboratories that were not reported by somatic testing laboratories and six variants with discrepant classifications between the designated germline and somatic testing laboratories. Three PVs identified by designated germline laboratories are targets for poly adenosine diphosphate-ribose polymerase (PARP) inhibitors and resulted in different treatment options. Of the PVs identified by designated germline laboratories, 60% (n = 12) were in genes with established associations to the patients' cancer, and 40% of the PVs were incidental. The majority (90%) of all discrepant findings, both contributory and incidental, changed management recommendations for these patients, highlighting the importance of comprehensive germline assessment. CONCLUSIONS Methods used by somatic laboratories, regardless of the inclusion of germline analysis, differ from those of designated germline laboratories for identifying germline PVs. Unrecognized germline PVs may harm patients by missing hereditary syndromes and targeted therapy opportunities (e.g. anti-programmed cell death protein 1 immunotherapy, PARP inhibitors). Clinicians should refer patients who meet the criteria for genetic evaluation regardless of somatic testing outcomes.
Collapse
Affiliation(s)
- K Pauley
- Family Cancer Assessment Clinic, Huntsman Cancer Institute, Salt Lake City, USA.
| | - C Koptiuch
- Family Cancer Assessment Clinic, Huntsman Cancer Institute, Salt Lake City, USA
| | - S Greenberg
- Family Cancer Assessment Clinic, Huntsman Cancer Institute, Salt Lake City, USA
| | - W Kohlmann
- Family Cancer Assessment Clinic, Huntsman Cancer Institute, Salt Lake City, USA
| | - J Jeter
- Department of Internal Medicine, Huntsman Cancer Institute, Salt Lake City, USA
| | - S Colonna
- Department of Internal Medicine, Huntsman Cancer Institute, Salt Lake City, USA
| | - T Werner
- Department of Internal Medicine, Huntsman Cancer Institute, Salt Lake City, USA
| | - C Kinsey
- Department of Internal Medicine, Huntsman Cancer Institute, Salt Lake City, USA
| | - G Gilcrease
- Department of Internal Medicine, Huntsman Cancer Institute, Salt Lake City, USA
| | - J Weis
- Department of Internal Medicine, Huntsman Cancer Institute, Salt Lake City, USA
| | - J Whisenant
- Department of Medical Oncology and Hematology, Utah Cancer Specialists, Salt Lake City, USA
| | - V Florou
- Department of Internal Medicine, Huntsman Cancer Institute, Salt Lake City, USA
| | - I Garrido-Laguna
- Department of Internal Medicine, Huntsman Cancer Institute, Salt Lake City, USA
| |
Collapse
|
2
|
Blanco AM, Yang S, Michalski ST, Ouyang K, Hamlington B, Fulbright J, Erhard K, Kang HC, Jacobs M, Koptiuch C, Vig H, Silver E, Benson C, Massingham L, Lincoln SE, Nussbaum RL, Hampel H, Esplin ED. Abstract P4-06-02: Germline analysis of breast cancer patients with abnormal somatic results: Ancillary assessment or critical co-diagnostic? Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p4-06-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Tumor genetic testing (TGT) is increasingly used for planning cancer treatment and identifying appropriate clinical trials. Emerging literature shows that 4–12% of genetic variants identified on TGT are also present in the germline, conferring hereditary cancer risk. Germline genetic testing (GGT) guidelines were recently expanded to include the identification of a BRCA1/BRCA2 variant on TGT as an indication for germline analysis. We evaluated the diagnostic yield of current GGT guidelines by assessing the rate of pathogenic and likely pathogenic (P/LP) germline findings in a series of patients who had a variant identified on TGT and underwent GGT. Methods: We analyzed de-identified data from 185 sequential patients with various tumor types who had TGT and GGT. Personal and family histories were compared to all available NCCN guidelines for GGT. Results: Sixty-four of 185 patients (34.6%) had at least one P/LP germline variant, and among these patients, 42% (27/64) had variants in BRCA1/BRCA2. Variants in all but one patient (26/27) were also found on TGT. Fourteen of 27 (52%) patients had a personal diagnosis of cancer not typically associated with BRCA1/BRCA2, including colorectal (5), lung (3), and one each of cervical, cholangiocarcinoma, gastric, thymus, thyroid, and uterine. Furthermore, prior TGT results were the only reason GGT guidelines were met in 12 of 27 (44%) patients with germline BRCA1/BRCA2 variants. Among 34 patients with a personal history of breast or ovarian cancer, a P/LP germline variant was identified in nine (26%); the majority (5 of 9) were in non-BRCA1/BRCA2 genes including CDKN2A (1), FANCA (1), MUTYH (1), and PALB2 (2). Notably, the patient with the CDKN2A variant did not meet current breast cancer guidelines for GGT, and one patient with breast cancer and a germline BRCA2 mutation only met GGT guidelines due to prior TGT results. Discussion: Genetic testing guidelines have begun to reflect the opportunity for TGT to identify families at risk for hereditary cancer. Expanding GGT criteria to include TGT results is critical for capturing patients who may not otherwise receive GGT. Our data showed a substantial diagnostic yield in patients—including those with breast or ovarian cancer—who completed GGT after variant identification on TGT. Although current genetic testing guidelines capture the portion of these patients with a BRCA1/BRCA2 mutation identified with TGT, our data suggest that P/LP variants in other genes should also be considered during the evaluation of TGT results for subsequent GTG. Finally, the broad spectrum of tumor types with BRCA1/BRCA2 P/LP variants emphasizes the need for all clinicians, regardless of subspecialty, to be aware of current GTG recommendations when TGT identifies a BRCA1/BRCA2 variant and the potential implications of GTG, including targeted therapy, screening, prevention, and family testing.
Citation Format: Blanco AM, Yang S, Michalski ST, Ouyang K, Hamlington B, Fulbright J, Erhard K, Kang HC, Jacobs M, Koptiuch C, Vig H, Silver E, Benson C, Massingham L, Lincoln SE, Nussbaum RL, Hampel H, Esplin ED. Germline analysis of breast cancer patients with abnormal somatic results: Ancillary assessment or critical co-diagnostic? [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P4-06-02.
Collapse
Affiliation(s)
- AM Blanco
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - S Yang
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - ST Michalski
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - K Ouyang
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - B Hamlington
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - J Fulbright
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - K Erhard
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - HC Kang
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - M Jacobs
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - C Koptiuch
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - H Vig
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - E Silver
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - C Benson
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - L Massingham
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - SE Lincoln
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - RL Nussbaum
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - H Hampel
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| | - ED Esplin
- University of California San Francisco, San Francisco, CA; University of Michigan, Ann Arbor, MI; Huntsman Cancer Institute, Salt Lake City, UT; University of California Los Angeles, Los Angeles, CA; Invitae, San Francisco, CA; Rutgers Cancer Institute; Lifespan Cancer Institute; The Ohio State University
| |
Collapse
|